Susvimo

Overview

ranibizumab

VEGF directed antibody

• antiplatelet/anticoagulant effects
• thrombogenic effects

Avoid/Use Alternative

• tranexamic acid
Susvimo (ranibizumab intravitreal)

+

tranexamic acid

1 interaction

Avoid/Use Alternative

ranibizumab + tranexamic acid

avoid combo: combo may incr. risk of thromboembolism (additive effects)

• vaccinia immune globulin
Susvimo (ranibizumab intravitreal)

+

vaccinia immune globulin

1 interaction

Avoid/Use Alternative

ranibizumab + vaccinia immune globulin

use alternative or monitor thrombosis s/sx; use lowest vaccinia immune globulin concentration and infusion rate possible; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

Monitor/Modify Tx

• abemaciclib
Susvimo (ranibizumab intravitreal)

+

abemaciclib

1 interaction

Monitor/Modify Tx

ranibizumab + abemaciclib

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• abrocitinib
Susvimo (ranibizumab intravitreal)

+

abrocitinib

1 interaction

Monitor/Modify Tx

ranibizumab + abrocitinib

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• acalabrutinib
Susvimo (ranibizumab intravitreal)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

ranibizumab + acalabrutinib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• ado-trastuzumab emtansine
Susvimo (ranibizumab intravitreal)

+

ado-trastuzumab emtansine

1 interaction

Monitor/Modify Tx

ranibizumab + ado-trastuzumab emtansine

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• aflibercept
Susvimo (ranibizumab intravitreal)

+

aflibercept

1 interaction

Monitor/Modify Tx

ranibizumab + aflibercept

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• alteplase
Susvimo (ranibizumab intravitreal)

+

alteplase

1 interaction

Monitor/Modify Tx

ranibizumab + alteplase

monitor bleeding s/sx; consider holding alteplase prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• aminocaproic acid
Susvimo (ranibizumab intravitreal)

+

aminocaproic acid

1 interaction

Monitor/Modify Tx

ranibizumab + aminocaproic acid

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• anacaulase topical
Susvimo (ranibizumab intravitreal)

+

anacaulase topical

1 interaction

Monitor/Modify Tx

ranibizumab + anacaulase topical

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• anagrelide
Susvimo (ranibizumab intravitreal)

+

anagrelide

1 interaction

Monitor/Modify Tx

ranibizumab + anagrelide

monitor bleeding s/sx; consider holding anagrelide prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• angiotensin II
Susvimo (ranibizumab intravitreal)

+

angiotensin II

1 interaction

Monitor/Modify Tx

ranibizumab + angiotensin II

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• anthrax immune globulin
Susvimo (ranibizumab intravitreal)

+

anthrax immune globulin

1 interaction

Monitor/Modify Tx

ranibizumab + anthrax immune globulin

monitor thrombosis s/sx; use lowest anthrax immune globulin infusion rate possible; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• anti-inhibitor coagulant complex
Susvimo (ranibizumab intravitreal)

+

anti-inhibitor coagulant complex

1 interaction

Monitor/Modify Tx

ranibizumab + anti-inhibitor coagulant complex

monitor thrombosis s/sx, especially w/ anti-inhibitor coagulant complex dose >100 units/kg; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• antihemophilic factor (factor VIII)/von Willebrand factor complex
Susvimo (ranibizumab intravitreal)

+

antihemophilic factor (factor VIII)/ von Willebrand factor complex

1 interaction

Monitor/Modify Tx

ranibizumab + antihemophilic factor (factor VIII)/ von Willebrand factor complex

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• antithrombin
Susvimo (ranibizumab intravitreal)

+

antithrombin

1 interaction

Monitor/Modify Tx

ranibizumab + antithrombin

monitor bleeding s/sx; consider holding antithrombin prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• apixaban
Susvimo (ranibizumab intravitreal)

+

apixaban

1 interaction

Monitor/Modify Tx

ranibizumab + apixaban

monitor bleeding s/sx; consider holding apixaban prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• argatroban
Susvimo (ranibizumab intravitreal)

+

argatroban

1 interaction

Monitor/Modify Tx

ranibizumab + argatroban

monitor bleeding s/sx; consider holding argatroban prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• asciminib
Susvimo (ranibizumab intravitreal)

+

asciminib

1 interaction

Monitor/Modify Tx

ranibizumab + asciminib

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• asparaginase
Susvimo (ranibizumab intravitreal)

+

asparaginase

1 interaction

Monitor/Modify Tx

ranibizumab + asparaginase

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• aspirin
Susvimo (ranibizumab intravitreal)

+

aspirin

1 interaction

Monitor/Modify Tx

ranibizumab + aspirin

monitor bleeding s/sx; consider holding aspirin prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• atidarsagene autotemcel
Susvimo (ranibizumab intravitreal)

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

ranibizumab + atidarsagene autotemcel

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• avapritinib
Susvimo (ranibizumab intravitreal)

+

avapritinib

1 interaction

Monitor/Modify Tx

ranibizumab + avapritinib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• avatrombopag
Susvimo (ranibizumab intravitreal)

+

avatrombopag

1 interaction

Monitor/Modify Tx

ranibizumab + avatrombopag

monitor platelets, thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• axitinib
Susvimo (ranibizumab intravitreal)

+

axitinib

1 interaction

Monitor/Modify Tx

ranibizumab + axitinib

monitor bleeding, thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• baricitinib
Susvimo (ranibizumab intravitreal)

+

baricitinib

1 interaction

Monitor/Modify Tx

ranibizumab + baricitinib

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• bazedoxifene
Susvimo (ranibizumab intravitreal)

+

bazedoxifene

1 interaction

Monitor/Modify Tx

ranibizumab + bazedoxifene

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• bevacizumab
Susvimo (ranibizumab intravitreal)

+

bevacizumab

1 interaction

Monitor/Modify Tx

ranibizumab + bevacizumab

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• binimetinib
Susvimo (ranibizumab intravitreal)

+

binimetinib

1 interaction

Monitor/Modify Tx

ranibizumab + binimetinib

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• bivalirudin
Susvimo (ranibizumab intravitreal)

+

bivalirudin

1 interaction

Monitor/Modify Tx

ranibizumab + bivalirudin

monitor bleeding s/sx; consider holding bivalirudin prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• botulism immune globulin
Susvimo (ranibizumab intravitreal)

+

botulism immune globulin

1 interaction

Monitor/Modify Tx

ranibizumab + botulism immune globulin

monitor thrombosis s/sx; use lowest botulism immune globulin infusion rate possible; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• brolucizumab
Susvimo (ranibizumab intravitreal)

+

brolucizumab

1 interaction

Monitor/Modify Tx

ranibizumab + brolucizumab

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• bromelain
Susvimo (ranibizumab intravitreal)

+

bromelain

1 interaction

Monitor/Modify Tx

ranibizumab + bromelain

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• bromfenac ophthalmic
Susvimo (ranibizumab intravitreal)

+

bromfenac ophthalmic

1 interaction

Monitor/Modify Tx

ranibizumab + bromfenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• C1 esterase inhibitor
Susvimo (ranibizumab intravitreal)

+

C1 esterase inhibitor

1 interaction

Monitor/Modify Tx

ranibizumab + C1 esterase inhibitor

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• cabozantinib
Susvimo (ranibizumab intravitreal)

+

cabozantinib

1 interaction

Monitor/Modify Tx

ranibizumab + cabozantinib

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• calaspargase
Susvimo (ranibizumab intravitreal)

+

calaspargase

1 interaction

Monitor/Modify Tx

ranibizumab + calaspargase

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower is ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• cangrelor
Susvimo (ranibizumab intravitreal)

+

cangrelor

1 interaction

Monitor/Modify Tx

ranibizumab + cangrelor

monitor bleeding s/sx; consider holding cangrelor prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• caplacizumab
Susvimo (ranibizumab intravitreal)

+

caplacizumab

1 interaction

Monitor/Modify Tx

ranibizumab + caplacizumab

monitor bleeding s/sx; consider holding caplacizumab prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• carfilzomib
Susvimo (ranibizumab intravitreal)

+

carfilzomib

1 interaction

Monitor/Modify Tx

ranibizumab + carfilzomib

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• celecoxib
Susvimo (ranibizumab intravitreal)

+

celecoxib

1 interaction

Monitor/Modify Tx

ranibizumab + celecoxib

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• chorionic gonadotropin
Susvimo (ranibizumab intravitreal)

+

chorionic gonadotropin

1 interaction

Monitor/Modify Tx

ranibizumab + chorionic gonadotropin

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• cilostazol
Susvimo (ranibizumab intravitreal)

+

cilostazol

1 interaction

Monitor/Modify Tx

ranibizumab + cilostazol

monitor bleeding s/sx; consider holding cilostazol prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• citalopram
Susvimo (ranibizumab intravitreal)

+

citalopram

1 interaction

Monitor/Modify Tx

ranibizumab + citalopram

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• clopidogrel
Susvimo (ranibizumab intravitreal)

+

clopidogrel

1 interaction

Monitor/Modify Tx

ranibizumab + clopidogrel

monitor bleeding s/sx; consider holding clopidogrel prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• clozapine
Susvimo (ranibizumab intravitreal)

+

clozapine

1 interaction

Monitor/Modify Tx

ranibizumab + clozapine

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• coagulation factor IX
Susvimo (ranibizumab intravitreal)

+

coagulation factor IX

1 interaction

Monitor/Modify Tx

ranibizumab + coagulation factor IX

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• coagulation factor VIIa
Susvimo (ranibizumab intravitreal)

+

coagulation factor VIIa

1 interaction

Monitor/Modify Tx

ranibizumab + coagulation factor VIIa

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• coagulation factor XIII A-subunit
Susvimo (ranibizumab intravitreal)

+

coagulation factor XIII A-subunit

1 interaction

Monitor/Modify Tx

ranibizumab + coagulation factor XIII A-subunit

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• concizumab
Susvimo (ranibizumab intravitreal)

+

concizumab

1 interaction

Monitor/Modify Tx

ranibizumab + concizumab

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• cytomegalovirus immune globulin
Susvimo (ranibizumab intravitreal)

+

cytomegalovirus immune globulin

1 interaction

Monitor/Modify Tx

ranibizumab + cytomegalovirus immune globulin

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• dabigatran
Susvimo (ranibizumab intravitreal)

+

dabigatran

1 interaction

Monitor/Modify Tx

ranibizumab + dabigatran

monitor bleeding s/sx; consider holding dabigatran prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• dalteparin
Susvimo (ranibizumab intravitreal)

+

dalteparin

1 interaction

Monitor/Modify Tx

ranibizumab + dalteparin

monitor bleeding s/sx; consider holding dalteparin prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• danazol
Susvimo (ranibizumab intravitreal)

+

danazol

1 interaction

Monitor/Modify Tx

ranibizumab + danazol

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• danshen
Susvimo (ranibizumab intravitreal)

+

danshen

1 interaction

Monitor/Modify Tx

ranibizumab + danshen

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• darbepoetin alfa
Susvimo (ranibizumab intravitreal)

+

darbepoetin alfa

1 interaction

Monitor/Modify Tx

ranibizumab + darbepoetin alfa

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• dasatinib
Susvimo (ranibizumab intravitreal)

+

dasatinib

1 interaction

Monitor/Modify Tx

ranibizumab + dasatinib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• defibrotide
Susvimo (ranibizumab intravitreal)

+

defibrotide

1 interaction

Monitor/Modify Tx

ranibizumab + defibrotide

monitor bleeding s/sx; consider holding defibrotide prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• deflazacort
Susvimo (ranibizumab intravitreal)

+

deflazacort

1 interaction

Monitor/Modify Tx

ranibizumab + deflazacort

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• desogestrel (contraceptive)
Susvimo (ranibizumab intravitreal)

+

desogestrel (contraceptive)

1 interaction

Monitor/Modify Tx

ranibizumab + desogestrel (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• desvenlafaxine
Susvimo (ranibizumab intravitreal)

+

desvenlafaxine

1 interaction

Monitor/Modify Tx

ranibizumab + desvenlafaxine

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• deuruxolitinib
Susvimo (ranibizumab intravitreal)

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

ranibizumab + deuruxolitinib

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• dexamethasone
Susvimo (ranibizumab intravitreal)

+

dexamethasone

1 interaction

Monitor/Modify Tx

ranibizumab + dexamethasone

monitor thrombosis s/sx, especially if multiple myeloma use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• diclofenac
Susvimo (ranibizumab intravitreal)

+

diclofenac

1 interaction

Monitor/Modify Tx

ranibizumab + diclofenac

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use; use lowest effective diclofenac dose, shortest effective tx duration: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• diclofenac ophthalmic
Susvimo (ranibizumab intravitreal)

+

diclofenac ophthalmic

1 interaction

Monitor/Modify Tx

ranibizumab + diclofenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• diclofenac topical
Susvimo (ranibizumab intravitreal)

+

diclofenac topical

1 interaction

Monitor/Modify Tx

ranibizumab + diclofenac topical

monitor bleeding or thrombosis s/sx; use lowest effective diclofenac dose, shortest effective tx duration; risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• dienogest (contraceptive)
Susvimo (ranibizumab intravitreal)

+

dienogest (contraceptive)

1 interaction

Monitor/Modify Tx

ranibizumab + dienogest (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• diflunisal
Susvimo (ranibizumab intravitreal)

+

diflunisal

1 interaction

Monitor/Modify Tx

ranibizumab + diflunisal

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use; use lowest effective diflunisal dose, shortest effective tx duration: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• diosmin
Susvimo (ranibizumab intravitreal)

+

diosmin

1 interaction

Monitor/Modify Tx

ranibizumab + diosmin

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• dipyridamole
Susvimo (ranibizumab intravitreal)

+

dipyridamole

1 interaction

Monitor/Modify Tx

ranibizumab + dipyridamole

monitor bleeding s/sx; consider holding dipyridamole prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• drospirenone (contraceptive)
Susvimo (ranibizumab intravitreal)

+

drospirenone (contraceptive)

1 interaction

Monitor/Modify Tx

ranibizumab + drospirenone (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• drospirenone (hormone replacement)
Susvimo (ranibizumab intravitreal)

+

drospirenone (hormone replacement)

1 interaction

Monitor/Modify Tx

ranibizumab + drospirenone (hormone replacement)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• duloxetine
Susvimo (ranibizumab intravitreal)

+

duloxetine

1 interaction

Monitor/Modify Tx

ranibizumab + duloxetine

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• edoxaban
Susvimo (ranibizumab intravitreal)

+

edoxaban

1 interaction

Monitor/Modify Tx

ranibizumab + edoxaban

monitor bleeding s/sx; consider holding edoxaban prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• eltrombopag
Susvimo (ranibizumab intravitreal)

+

eltrombopag

1 interaction

Monitor/Modify Tx

ranibizumab + eltrombopag

monitor platelets, thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• encorafenib
Susvimo (ranibizumab intravitreal)

+

encorafenib

1 interaction

Monitor/Modify Tx

ranibizumab + encorafenib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• enoxaparin
Susvimo (ranibizumab intravitreal)

+

enoxaparin

1 interaction

Monitor/Modify Tx

ranibizumab + enoxaparin

monitor bleeding s/sx; consider holding enoxaparin prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• epirubicin
Susvimo (ranibizumab intravitreal)

+

epirubicin

1 interaction

Monitor/Modify Tx

ranibizumab + epirubicin

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• epoetin alfa
Susvimo (ranibizumab intravitreal)

+

epoetin alfa

1 interaction

Monitor/Modify Tx

ranibizumab + epoetin alfa

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• epoprostenol
Susvimo (ranibizumab intravitreal)

+

epoprostenol

1 interaction

Monitor/Modify Tx

ranibizumab + epoprostenol

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• eptifibatide
Susvimo (ranibizumab intravitreal)

+

eptifibatide

1 interaction

Monitor/Modify Tx

ranibizumab + eptifibatide

monitor bleeding s/sx; consider holding eptifibatide prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• escitalopram
Susvimo (ranibizumab intravitreal)

+

escitalopram

1 interaction

Monitor/Modify Tx

ranibizumab + escitalopram

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• estetrol (contraceptive)
Susvimo (ranibizumab intravitreal)

+

estetrol (contraceptive)

1 interaction

Monitor/Modify Tx

ranibizumab + estetrol (contraceptive)

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• estradiol (contraceptive)
Susvimo (ranibizumab intravitreal)

+

estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

ranibizumab + estradiol (contraceptive)

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• estradiol (hormone replacement)
Susvimo (ranibizumab intravitreal)

+

estradiol (hormone replacement)

1 interaction

Monitor/Modify Tx

ranibizumab + estradiol (hormone replacement)

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• estrogens, conjugated (hormone replacement)
Susvimo (ranibizumab intravitreal)

+

estrogens, conjugated (hormone replacement)

1 interaction

Monitor/Modify Tx

ranibizumab + estrogens, conjugated (hormone replacement)

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• estrogens, esterified (hormone replacement)
Susvimo (ranibizumab intravitreal)

+

estrogens, esterified (hormone replacement)

1 interaction

Monitor/Modify Tx

ranibizumab + estrogens, esterified (hormone replacement)

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• ethinyl estradiol (contraceptive)
Susvimo (ranibizumab intravitreal)

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

ranibizumab + ethinyl estradiol (contraceptive)

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• ethinyl estradiol (hormone replacement)
Susvimo (ranibizumab intravitreal)

+

ethinyl estradiol (hormone replacement)

1 interaction

Monitor/Modify Tx

ranibizumab + ethinyl estradiol (hormone replacement)

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• ethynodiol (contraceptive)
Susvimo (ranibizumab intravitreal)

+

ethynodiol (contraceptive)

1 interaction

Monitor/Modify Tx

ranibizumab + ethynodiol (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• etodolac
Susvimo (ranibizumab intravitreal)

+

etodolac

1 interaction

Monitor/Modify Tx

ranibizumab + etodolac

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use; use lowest effective etodolac dose, shortest effective tx duration: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• etonogestrel (contraceptive)
Susvimo (ranibizumab intravitreal)

+

etonogestrel (contraceptive)

1 interaction

Monitor/Modify Tx

ranibizumab + etonogestrel (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• evening primrose oil
Susvimo (ranibizumab intravitreal)

+

evening primrose oil

1 interaction

Monitor/Modify Tx

ranibizumab + evening primrose oil

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• everolimus
Susvimo (ranibizumab intravitreal)

+

everolimus

1 interaction

Monitor/Modify Tx

ranibizumab + everolimus

monitor thrombosis s/sx, especially if immunosuppressant use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• factor XIII concentrate
Susvimo (ranibizumab intravitreal)

+

factor XIII concentrate

1 interaction

Monitor/Modify Tx

ranibizumab + factor XIII concentrate

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• faricimab
Susvimo (ranibizumab intravitreal)

+

faricimab

1 interaction

Monitor/Modify Tx

ranibizumab + faricimab

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• fedratinib
Susvimo (ranibizumab intravitreal)

+

fedratinib

1 interaction

Monitor/Modify Tx

ranibizumab + fedratinib

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• fenofibrate
Susvimo (ranibizumab intravitreal)

+

fenofibrate

1 interaction

Monitor/Modify Tx

ranibizumab + fenofibrate

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• fenofibric acid
Susvimo (ranibizumab intravitreal)

+

fenofibric acid

1 interaction

Monitor/Modify Tx

ranibizumab + fenofibric acid

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• fenoprofen
Susvimo (ranibizumab intravitreal)

+

fenoprofen

1 interaction

Monitor/Modify Tx

ranibizumab + fenoprofen

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• fenugreek
Susvimo (ranibizumab intravitreal)

+

fenugreek

1 interaction

Monitor/Modify Tx

ranibizumab + fenugreek

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• fitusiran
Susvimo (ranibizumab intravitreal)

+

fitusiran

1 interaction

Monitor/Modify Tx

ranibizumab + fitusiran

monitor antithrombin activity level, thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• fluoxetine
Susvimo (ranibizumab intravitreal)

+

fluoxetine

1 interaction

Monitor/Modify Tx

ranibizumab + fluoxetine

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• flurbiprofen
Susvimo (ranibizumab intravitreal)

+

flurbiprofen

1 interaction

Monitor/Modify Tx

ranibizumab + flurbiprofen

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use; use lowest effective flurbiprofen dose, shortest effective tx duration: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• flurbiprofen ophthalmic
Susvimo (ranibizumab intravitreal)

+

flurbiprofen ophthalmic

1 interaction

Monitor/Modify Tx

ranibizumab + flurbiprofen ophthalmic

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• fluvoxamine
Susvimo (ranibizumab intravitreal)

+

fluvoxamine

1 interaction

Monitor/Modify Tx

ranibizumab + fluvoxamine

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• follitropin
Susvimo (ranibizumab intravitreal)

+

follitropin

1 interaction

Monitor/Modify Tx

ranibizumab + follitropin

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• fondaparinux
Susvimo (ranibizumab intravitreal)

+

fondaparinux

1 interaction

Monitor/Modify Tx

ranibizumab + fondaparinux

monitor bleeding s/sx; consider holding fondaparinux prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• fruquintinib
Susvimo (ranibizumab intravitreal)

+

fruquintinib

1 interaction

Monitor/Modify Tx

ranibizumab + fruquintinib

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of thromboembolism, ocular hemorrhage (additive effects)

• garlic
Susvimo (ranibizumab intravitreal)

+

garlic

1 interaction

Monitor/Modify Tx

ranibizumab + garlic

monitor bleeding s/sx, especially w/ supplemental garlic; dietary intake OK: combo may incr. risk of ocular hemorrhage (additive effects)

• gemtuzumab ozogamicin
Susvimo (ranibizumab intravitreal)

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

ranibizumab + gemtuzumab ozogamicin

monitor platelets, bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• ginkgo
Susvimo (ranibizumab intravitreal)

+

ginkgo

1 interaction

Monitor/Modify Tx

ranibizumab + ginkgo

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• heparin
Susvimo (ranibizumab intravitreal)

+

heparin

1 interaction

Monitor/Modify Tx

ranibizumab + heparin

monitor bleeding s/sx; consider holding heparin prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• hepatitis B immune globulin
Susvimo (ranibizumab intravitreal)

+

hepatitis B immune globulin

1 interaction

Monitor/Modify Tx

ranibizumab + hepatitis B immune globulin

monitor thrombosis s/sx; use lowest hepatitis B immune globulin infusion rate possible; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• ibrutinib
Susvimo (ranibizumab intravitreal)

+

ibrutinib

1 interaction

Monitor/Modify Tx

ranibizumab + ibrutinib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• ibuprofen
Susvimo (ranibizumab intravitreal)

+

ibuprofen

1 interaction

Monitor/Modify Tx

ranibizumab + ibuprofen

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use; use lowest effective ibuprofen dose, shortest effective tx duration: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• ibuprofen lysine
Susvimo (ranibizumab intravitreal)

+

ibuprofen lysine

1 interaction

Monitor/Modify Tx

ranibizumab + ibuprofen lysine

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• icosapent ethyl
Susvimo (ranibizumab intravitreal)

+

icosapent ethyl

1 interaction

Monitor/Modify Tx

ranibizumab + icosapent ethyl

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• iloprost inhaled
Susvimo (ranibizumab intravitreal)

+

iloprost inhaled

1 interaction

Monitor/Modify Tx

ranibizumab + iloprost inhaled

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• imatinib
Susvimo (ranibizumab intravitreal)

+

imatinib

1 interaction

Monitor/Modify Tx

ranibizumab + imatinib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• immune globulin
Susvimo (ranibizumab intravitreal)

+

immune globulin

1 interaction

Monitor/Modify Tx

ranibizumab + immune globulin

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• indomethacin
Susvimo (ranibizumab intravitreal)

+

indomethacin

1 interaction

Monitor/Modify Tx

ranibizumab + indomethacin

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use; use lowest effective indomethacin dose, shortest effective tx duration: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• iohexol
Susvimo (ranibizumab intravitreal)

+

iohexol

1 interaction

Monitor/Modify Tx

ranibizumab + iohexol

if IV iohexol use, monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• iomeprol
Susvimo (ranibizumab intravitreal)

+

iomeprol

1 interaction

Monitor/Modify Tx

ranibizumab + iomeprol

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• iopamidol
Susvimo (ranibizumab intravitreal)

+

iopamidol

1 interaction

Monitor/Modify Tx

ranibizumab + iopamidol

if IV iopamidol use, monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• ketoprofen
Susvimo (ranibizumab intravitreal)

+

ketoprofen

1 interaction

Monitor/Modify Tx

ranibizumab + ketoprofen

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• ketorolac
Susvimo (ranibizumab intravitreal)

+

ketorolac

1 interaction

Monitor/Modify Tx

ranibizumab + ketorolac

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use; use lowest effective ketorolac dose, shortest effective tx duration: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• ketorolac ophthalmic
Susvimo (ranibizumab intravitreal)

+

ketorolac ophthalmic

1 interaction

Monitor/Modify Tx

ranibizumab + ketorolac ophthalmic

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• lazertinib
Susvimo (ranibizumab intravitreal)

+

lazertinib

1 interaction

Monitor/Modify Tx

ranibizumab + lazertinib

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• lenalidomide
Susvimo (ranibizumab intravitreal)

+

lenalidomide

1 interaction

Monitor/Modify Tx

ranibizumab + lenalidomide

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• lenvatinib
Susvimo (ranibizumab intravitreal)

+

lenvatinib

1 interaction

Monitor/Modify Tx

ranibizumab + lenvatinib

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• levomilnacipran
Susvimo (ranibizumab intravitreal)

+

levomilnacipran

1 interaction

Monitor/Modify Tx

ranibizumab + levomilnacipran

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• levonorgestrel (contraceptive)
Susvimo (ranibizumab intravitreal)

+

levonorgestrel (contraceptive)

1 interaction

Monitor/Modify Tx

ranibizumab + levonorgestrel (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• levonorgestrel (hormone replacement)
Susvimo (ranibizumab intravitreal)

+

levonorgestrel (hormone replacement)

1 interaction

Monitor/Modify Tx

ranibizumab + levonorgestrel (hormone replacement)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• lifileucel
Susvimo (ranibizumab intravitreal)

+

lifileucel

1 interaction

Monitor/Modify Tx

ranibizumab + lifileucel

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• luspatercept
Susvimo (ranibizumab intravitreal)

+

luspatercept

1 interaction

Monitor/Modify Tx

ranibizumab + luspatercept

if beta thalassemia use, monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• lusutrombopag
Susvimo (ranibizumab intravitreal)

+

lusutrombopag

1 interaction

Monitor/Modify Tx

ranibizumab + lusutrombopag

monitor platelets, thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• meclofenamate
Susvimo (ranibizumab intravitreal)

+

meclofenamate

1 interaction

Monitor/Modify Tx

ranibizumab + meclofenamate

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• medroxyprogesterone (contraceptive)
Susvimo (ranibizumab intravitreal)

+

medroxyprogesterone (contraceptive)

1 interaction

Monitor/Modify Tx

ranibizumab + medroxyprogesterone (contraceptive)

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• medroxyprogesterone (hormone replacement)
Susvimo (ranibizumab intravitreal)

+

medroxyprogesterone (hormone replacement)

1 interaction

Monitor/Modify Tx

ranibizumab + medroxyprogesterone (hormone replacement)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• mefenamic acid
Susvimo (ranibizumab intravitreal)

+

mefenamic acid

1 interaction

Monitor/Modify Tx

ranibizumab + mefenamic acid

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• megestrol
Susvimo (ranibizumab intravitreal)

+

megestrol

1 interaction

Monitor/Modify Tx

ranibizumab + megestrol

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• meloxicam
Susvimo (ranibizumab intravitreal)

+

meloxicam

1 interaction

Monitor/Modify Tx

ranibizumab + meloxicam

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use; use lowest effective meloxicam dose, shortest effective tx duration: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• menotropins
Susvimo (ranibizumab intravitreal)

+

menotropins

1 interaction

Monitor/Modify Tx

ranibizumab + menotropins

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• methoxy polyethylene glycol-epoetin beta
Susvimo (ranibizumab intravitreal)

+

methoxy polyethylene glycol-epoetin beta

1 interaction

Monitor/Modify Tx

ranibizumab + methoxy polyethylene glycol-epoetin beta

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• methyl salicylate topical
Susvimo (ranibizumab intravitreal)

+

methyl salicylate topical

1 interaction

Monitor/Modify Tx

ranibizumab + methyl salicylate topical

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, systemic salicylate absorption may occur from topical use)

• methyltestosterone
Susvimo (ranibizumab intravitreal)

+

methyltestosterone

1 interaction

Monitor/Modify Tx

ranibizumab + methyltestosterone

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• milnacipran
Susvimo (ranibizumab intravitreal)

+

milnacipran

1 interaction

Monitor/Modify Tx

ranibizumab + milnacipran

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• mitotane
Susvimo (ranibizumab intravitreal)

+

mitotane

1 interaction

Monitor/Modify Tx

ranibizumab + mitotane

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• momelotinib
Susvimo (ranibizumab intravitreal)

+

momelotinib

1 interaction

Monitor/Modify Tx

ranibizumab + momelotinib

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• nabumetone
Susvimo (ranibizumab intravitreal)

+

nabumetone

1 interaction

Monitor/Modify Tx

ranibizumab + nabumetone

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• naproxen
Susvimo (ranibizumab intravitreal)

+

naproxen

1 interaction

Monitor/Modify Tx

ranibizumab + naproxen

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use; use lowest effective naproxen dose, shortest effective tx duration: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• nattokinase
Susvimo (ranibizumab intravitreal)

+

nattokinase

1 interaction

Monitor/Modify Tx

ranibizumab + nattokinase

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• necitumumab
Susvimo (ranibizumab intravitreal)

+

necitumumab

1 interaction

Monitor/Modify Tx

ranibizumab + necitumumab

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• nepafenac ophthalmic
Susvimo (ranibizumab intravitreal)

+

nepafenac ophthalmic

1 interaction

Monitor/Modify Tx

ranibizumab + nepafenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• niacin (vitamin B3)
Susvimo (ranibizumab intravitreal)

+

niacin (vitamin B3)

1 interaction

Monitor/Modify Tx

ranibizumab + niacin (vitamin B3)

monitor platelets, bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• nilotinib
Susvimo (ranibizumab intravitreal)

+

nilotinib

1 interaction

Monitor/Modify Tx

ranibizumab + nilotinib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• nintedanib
Susvimo (ranibizumab intravitreal)

+

nintedanib

1 interaction

Monitor/Modify Tx

ranibizumab + nintedanib

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• norelgestromin (contraceptive)
Susvimo (ranibizumab intravitreal)

+

norelgestromin (contraceptive)

1 interaction

Monitor/Modify Tx

ranibizumab + norelgestromin (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• norethindrone (contraceptive)
Susvimo (ranibizumab intravitreal)

+

norethindrone (contraceptive)

1 interaction

Monitor/Modify Tx

ranibizumab + norethindrone (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• norethindrone acetate (hormone replacement)
Susvimo (ranibizumab intravitreal)

+

norethindrone acetate (hormone replacement)

1 interaction

Monitor/Modify Tx

ranibizumab + norethindrone acetate (hormone replacement)

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• norgestimate (contraceptive)
Susvimo (ranibizumab intravitreal)

+

norgestimate (contraceptive)

1 interaction

Monitor/Modify Tx

ranibizumab + norgestimate (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• norgestimate (hormone replacement)
Susvimo (ranibizumab intravitreal)

+

norgestimate (hormone replacement)

1 interaction

Monitor/Modify Tx

ranibizumab + norgestimate (hormone replacement)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• norgestrel (contraceptive)
Susvimo (ranibizumab intravitreal)

+

norgestrel (contraceptive)

1 interaction

Monitor/Modify Tx

ranibizumab + norgestrel (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• nusinersen
Susvimo (ranibizumab intravitreal)

+

nusinersen

1 interaction

Monitor/Modify Tx

ranibizumab + nusinersen

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• olaparib
Susvimo (ranibizumab intravitreal)

+

olaparib

1 interaction

Monitor/Modify Tx

ranibizumab + olaparib

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• omega-3-acid
Susvimo (ranibizumab intravitreal)

+

omega-3-acid

1 interaction

Monitor/Modify Tx

ranibizumab + omega-3-acid

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• ospemifene
Susvimo (ranibizumab intravitreal)

+

ospemifene

1 interaction

Monitor/Modify Tx

ranibizumab + ospemifene

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• oxaliplatin
Susvimo (ranibizumab intravitreal)

+

oxaliplatin

1 interaction

Monitor/Modify Tx

ranibizumab + oxaliplatin

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• oxaprozin
Susvimo (ranibizumab intravitreal)

+

oxaprozin

1 interaction

Monitor/Modify Tx

ranibizumab + oxaprozin

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• pacritinib
Susvimo (ranibizumab intravitreal)

+

pacritinib

1 interaction

Monitor/Modify Tx

ranibizumab + pacritinib

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• paroxetine
Susvimo (ranibizumab intravitreal)

+

paroxetine

1 interaction

Monitor/Modify Tx

ranibizumab + paroxetine

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• pazopanib
Susvimo (ranibizumab intravitreal)

+

pazopanib

1 interaction

Monitor/Modify Tx

ranibizumab + pazopanib

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• pegaspargase
Susvimo (ranibizumab intravitreal)

+

pegaspargase

1 interaction

Monitor/Modify Tx

ranibizumab + pegaspargase

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower is ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• penicillin G
Susvimo (ranibizumab intravitreal)

+

penicillin G

1 interaction

Monitor/Modify Tx

ranibizumab + penicillin G

monitor bleeding s/sx, especially w/ large penicillin G doses and/or concomitant renal impairment: combo may incr. risk of ocular hemorrhage (additive effects)

• pentosan polysulfate sodium
Susvimo (ranibizumab intravitreal)

+

pentosan polysulfate sodium

1 interaction

Monitor/Modify Tx

ranibizumab + pentosan polysulfate sodium

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• pentoxifylline
Susvimo (ranibizumab intravitreal)

+

pentoxifylline

1 interaction

Monitor/Modify Tx

ranibizumab + pentoxifylline

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• piperacillin
Susvimo (ranibizumab intravitreal)

+

piperacillin

1 interaction

Monitor/Modify Tx

ranibizumab + piperacillin

monitor bleeding s/sx, especially w/ prolonged piperacillin tx and/or concomitant renal impairment: combo may incr. risk of ocular hemorrhage (additive effects)

• piroxicam
Susvimo (ranibizumab intravitreal)

+

piroxicam

1 interaction

Monitor/Modify Tx

ranibizumab + piroxicam

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use; use lowest effective piroxicam dose, shortest effective tx duration: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• pirtobrutinib
Susvimo (ranibizumab intravitreal)

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

ranibizumab + pirtobrutinib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• plasminogen, human
Susvimo (ranibizumab intravitreal)

+

plasminogen, human

1 interaction

Monitor/Modify Tx

ranibizumab + plasminogen, human

monitor bleeding s/sx, especially during and x4h after plasminogen infusion: combo may incr. risk of ocular hemorrhage (additive effects)

• pomalidomide
Susvimo (ranibizumab intravitreal)

+

pomalidomide

1 interaction

Monitor/Modify Tx

ranibizumab + pomalidomide

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• ponatinib
Susvimo (ranibizumab intravitreal)

+

ponatinib

1 interaction

Monitor/Modify Tx

ranibizumab + ponatinib

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• porfimer
Susvimo (ranibizumab intravitreal)

+

porfimer

1 interaction

Monitor/Modify Tx

ranibizumab + porfimer

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• pralsetinib
Susvimo (ranibizumab intravitreal)

+

pralsetinib

1 interaction

Monitor/Modify Tx

ranibizumab + pralsetinib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• prasugrel
Susvimo (ranibizumab intravitreal)

+

prasugrel

1 interaction

Monitor/Modify Tx

ranibizumab + prasugrel

monitor bleeding s/sx; consider holding prasugrel prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• progesterone (hormone replacement)
Susvimo (ranibizumab intravitreal)

+

progesterone (hormone replacement)

1 interaction

Monitor/Modify Tx

ranibizumab + progesterone (hormone replacement)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• progesterone vaginal (hormone replacement)
Susvimo (ranibizumab intravitreal)

+

progesterone vaginal (hormone replacement)

1 interaction

Monitor/Modify Tx

ranibizumab + progesterone vaginal (hormone replacement)

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• prothrombin complex concentrate (human)
Susvimo (ranibizumab intravitreal)

+

prothrombin complex concentrate (human)

1 interaction

Monitor/Modify Tx

ranibizumab + prothrombin complex concentrate (human)

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• raloxifene
Susvimo (ranibizumab intravitreal)

+

raloxifene

1 interaction

Monitor/Modify Tx

ranibizumab + raloxifene

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• ramucirumab
Susvimo (ranibizumab intravitreal)

+

ramucirumab

1 interaction

Monitor/Modify Tx

ranibizumab + ramucirumab

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• regorafenib
Susvimo (ranibizumab intravitreal)

+

regorafenib

1 interaction

Monitor/Modify Tx

ranibizumab + regorafenib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• resveratrol
Susvimo (ranibizumab intravitreal)

+

resveratrol

1 interaction

Monitor/Modify Tx

ranibizumab + resveratrol

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• reteplase
Susvimo (ranibizumab intravitreal)

+

reteplase

1 interaction

Monitor/Modify Tx

ranibizumab + reteplase

monitor bleeding s/sx; consider holding reteplase prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• revakinagene taroretcel
Susvimo (ranibizumab intravitreal)

+

revakinagene taroretcel

1 interaction

Monitor/Modify Tx

ranibizumab + revakinagene taroretcel

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• Rho(D) immune globulin
Susvimo (ranibizumab intravitreal)

+

Rho(D) immune globulin

1 interaction

Monitor/Modify Tx

ranibizumab + Rho(D) immune globulin

monitor thrombosis s/sx; use lowest Rho(D) immune globulin infusion rate possible; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• ritlecitinib
Susvimo (ranibizumab intravitreal)

+

ritlecitinib

1 interaction

Monitor/Modify Tx

ranibizumab + ritlecitinib

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• rivaroxaban
Susvimo (ranibizumab intravitreal)

+

rivaroxaban

1 interaction

Monitor/Modify Tx

ranibizumab + rivaroxaban

monitor bleeding s/sx; consider holding rivaroxaban prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• romiplostim
Susvimo (ranibizumab intravitreal)

+

romiplostim

1 interaction

Monitor/Modify Tx

ranibizumab + romiplostim

monitor platelets, thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• ruxolitinib
Susvimo (ranibizumab intravitreal)

+

ruxolitinib

1 interaction

Monitor/Modify Tx

ranibizumab + ruxolitinib

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• ruxolitinib topical
Susvimo (ranibizumab intravitreal)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

ranibizumab + ruxolitinib topical

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• salsalate
Susvimo (ranibizumab intravitreal)

+

salsalate

1 interaction

Monitor/Modify Tx

ranibizumab + salsalate

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• saw palmetto
Susvimo (ranibizumab intravitreal)

+

saw palmetto

1 interaction

Monitor/Modify Tx

ranibizumab + saw palmetto

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• segesterone (contraceptive)
Susvimo (ranibizumab intravitreal)

+

segesterone (contraceptive)

1 interaction

Monitor/Modify Tx

ranibizumab + segesterone (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• selpercatinib
Susvimo (ranibizumab intravitreal)

+

selpercatinib

1 interaction

Monitor/Modify Tx

ranibizumab + selpercatinib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• selumetinib
Susvimo (ranibizumab intravitreal)

+

selumetinib

1 interaction

Monitor/Modify Tx

ranibizumab + selumetinib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, antiplatelet and anticoagulant effects augmented by vitamin E content in selumetinib capsules)

• sertraline
Susvimo (ranibizumab intravitreal)

+

sertraline

1 interaction

Monitor/Modify Tx

ranibizumab + sertraline

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• sipuleucel-T
Susvimo (ranibizumab intravitreal)

+

sipuleucel-T

1 interaction

Monitor/Modify Tx

ranibizumab + sipuleucel-T

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• sirolimus albumin-bound
Susvimo (ranibizumab intravitreal)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

ranibizumab + sirolimus albumin-bound

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• sodium tetradecyl sulfate
Susvimo (ranibizumab intravitreal)

+

sodium tetradecyl sulfate

1 interaction

Monitor/Modify Tx

ranibizumab + sodium tetradecyl sulfate

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• sorafenib
Susvimo (ranibizumab intravitreal)

+

sorafenib

1 interaction

Monitor/Modify Tx

ranibizumab + sorafenib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• sotatercept
Susvimo (ranibizumab intravitreal)

+

sotatercept

1 interaction

Monitor/Modify Tx

ranibizumab + sotatercept

monitor Hgb, platelets, bleeding or thrombosis s/sx: combo may incr. risk of thromboembolism, ocular hemorrhage (additive effects)

• sulindac
Susvimo (ranibizumab intravitreal)

+

sulindac

1 interaction

Monitor/Modify Tx

ranibizumab + sulindac

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• sunitinib
Susvimo (ranibizumab intravitreal)

+

sunitinib

1 interaction

Monitor/Modify Tx

ranibizumab + sunitinib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• tamoxifen
Susvimo (ranibizumab intravitreal)

+

tamoxifen

1 interaction

Monitor/Modify Tx

ranibizumab + tamoxifen

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• temsirolimus
Susvimo (ranibizumab intravitreal)

+

temsirolimus

1 interaction

Monitor/Modify Tx

ranibizumab + temsirolimus

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• tenecteplase
Susvimo (ranibizumab intravitreal)

+

tenecteplase

1 interaction

Monitor/Modify Tx

ranibizumab + tenecteplase

monitor bleeding s/sx; consider holding tenecteplase prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• testosterone
Susvimo (ranibizumab intravitreal)

+

testosterone

1 interaction

Monitor/Modify Tx

ranibizumab + testosterone

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• thalidomide
Susvimo (ranibizumab intravitreal)

+

thalidomide

1 interaction

Monitor/Modify Tx

ranibizumab + thalidomide

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• ticagrelor
Susvimo (ranibizumab intravitreal)

+

ticagrelor

1 interaction

Monitor/Modify Tx

ranibizumab + ticagrelor

monitor bleeding s/sx; consider holding ticagrelor prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• tipranavir
Susvimo (ranibizumab intravitreal)

+

tipranavir

1 interaction

Monitor/Modify Tx

ranibizumab + tipranavir

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• tirofiban
Susvimo (ranibizumab intravitreal)

+

tirofiban

1 interaction

Monitor/Modify Tx

ranibizumab + tirofiban

monitor bleeding s/sx; consider holding tirofiban prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• tisotumab vedotin
Susvimo (ranibizumab intravitreal)

+

tisotumab vedotin

1 interaction

Monitor/Modify Tx

ranibizumab + tisotumab vedotin

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• tivozanib
Susvimo (ranibizumab intravitreal)

+

tivozanib

1 interaction

Monitor/Modify Tx

ranibizumab + tivozanib

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• tofacitinib
Susvimo (ranibizumab intravitreal)

+

tofacitinib

1 interaction

Monitor/Modify Tx

ranibizumab + tofacitinib

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• tolmetin
Susvimo (ranibizumab intravitreal)

+

tolmetin

1 interaction

Monitor/Modify Tx

ranibizumab + tolmetin

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• toremifene
Susvimo (ranibizumab intravitreal)

+

toremifene

1 interaction

Monitor/Modify Tx

ranibizumab + toremifene

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• tovorafenib
Susvimo (ranibizumab intravitreal)

+

tovorafenib

1 interaction

Monitor/Modify Tx

ranibizumab + tovorafenib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• trametinib
Susvimo (ranibizumab intravitreal)

+

trametinib

1 interaction

Monitor/Modify Tx

ranibizumab + trametinib

monitor bleeding or thrombosis s/sx, especially w/ concomitant dabrafenib use; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)

• trazodone
Susvimo (ranibizumab intravitreal)

+

trazodone

1 interaction

Monitor/Modify Tx

ranibizumab + trazodone

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• treprostinil
Susvimo (ranibizumab intravitreal)

+

treprostinil

1 interaction

Monitor/Modify Tx

ranibizumab + treprostinil

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• tretinoin
Susvimo (ranibizumab intravitreal)

+

tretinoin

1 interaction

Monitor/Modify Tx

ranibizumab + tretinoin

monitor thrombosis s/sx, especially during 1st month of tretinoin use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• upadacitinib
Susvimo (ranibizumab intravitreal)

+

upadacitinib

1 interaction

Monitor/Modify Tx

ranibizumab + upadacitinib

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• vadadustat
Susvimo (ranibizumab intravitreal)

+

vadadustat

1 interaction

Monitor/Modify Tx

ranibizumab + vadadustat

monitor Hgb, thrombosis s/sx; use lowest effective vadadustat dose; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• valoctocogene roxaparvovec
Susvimo (ranibizumab intravitreal)

+

valoctocogene roxaparvovec

1 interaction

Monitor/Modify Tx

ranibizumab + valoctocogene roxaparvovec

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• valproic acid
Susvimo (ranibizumab intravitreal)

+

valproic acid

1 interaction

Monitor/Modify Tx

ranibizumab + valproic acid

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• vamorolone
Susvimo (ranibizumab intravitreal)

+

vamorolone

1 interaction

Monitor/Modify Tx

ranibizumab + vamorolone

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• vandetanib
Susvimo (ranibizumab intravitreal)

+

vandetanib

1 interaction

Monitor/Modify Tx

ranibizumab + vandetanib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• varicella zoster immune globulin
Susvimo (ranibizumab intravitreal)

+

varicella zoster immune globulin

1 interaction

Monitor/Modify Tx

ranibizumab + varicella zoster immune globulin

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• venlafaxine
Susvimo (ranibizumab intravitreal)

+

venlafaxine

1 interaction

Monitor/Modify Tx

ranibizumab + venlafaxine

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• vilazodone
Susvimo (ranibizumab intravitreal)

+

vilazodone

1 interaction

Monitor/Modify Tx

ranibizumab + vilazodone

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• vinpocetine
Susvimo (ranibizumab intravitreal)

+

vinpocetine

1 interaction

Monitor/Modify Tx

ranibizumab + vinpocetine

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• von Willebrand factor
Susvimo (ranibizumab intravitreal)

+

von Willebrand factor

1 interaction

Monitor/Modify Tx

ranibizumab + von Willebrand factor

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• vorapaxar
Susvimo (ranibizumab intravitreal)

+

vorapaxar

1 interaction

Monitor/Modify Tx

ranibizumab + vorapaxar

monitor bleeding s/sx; consider holding vorapaxar prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• vorinostat
Susvimo (ranibizumab intravitreal)

+

vorinostat

1 interaction

Monitor/Modify Tx

ranibizumab + vorinostat

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• vortioxetine
Susvimo (ranibizumab intravitreal)

+

vortioxetine

1 interaction

Monitor/Modify Tx

ranibizumab + vortioxetine

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• warfarin
Susvimo (ranibizumab intravitreal)

+

warfarin

1 interaction

Monitor/Modify Tx

ranibizumab + warfarin

monitor bleeding s/sx; consider holding warfarin prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• willow bark
Susvimo (ranibizumab intravitreal)

+

willow bark

1 interaction

Monitor/Modify Tx

ranibizumab + willow bark

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects, willow bark may contain salicylates)

• zanubrutinib
Susvimo (ranibizumab intravitreal)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

ranibizumab + zanubrutinib

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• ziv-aflibercept
Susvimo (ranibizumab intravitreal)

+

ziv-aflibercept

1 interaction

Monitor/Modify Tx

ranibizumab + ziv-aflibercept

monitor bleeding or thrombosis s/sx; thrombosis risk may be lower if ocular implant use: combo may incr. risk of ocular hemorrhage, thromboembolism (additive effects)